Bio-Rad (BIO) Down 5.5% Since Last Earnings Report: Can It Rebound?

Zacks11-30

A month has gone by since the last earnings report for Bio-Rad Laboratories (BIO). Shares have lost about 5.5% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2487986615?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/0K2vxHTAGj_tGrBqjPJ8Cg--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/f889276f4a638f3c7a79c0e3e6b768c1","is_english":true,"pubTime":"2024-11-30 00:31","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2487986615","market":"us","top_or_hot":-1,"title":"Bio-Rad (BIO) Down 5.5% Since Last Earnings Report: Can It Rebound?","media":"Zacks","content":"<div>\n<p>A month has gone by since the last earnings report for Bio-Rad Laboratories (BIO). Shares have lost about 5.5% in that time frame, underperforming the S&P 500.\nWill the recent negative trend continue ...</p>\n\n<a href=\"https://finance.yahoo.com/news/bio-rad-bio-down-5-163145298.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bio-Rad (BIO) Down 5.5% Since Last Earnings Report: Can It Rebound?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBio-Rad (BIO) Down 5.5% Since Last Earnings Report: Can It Rebound?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-30 00:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/bio-rad-bio-down-5-163145298.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>A month has gone by since the last earnings report for Bio-Rad Laboratories (BIO). Shares have lost about 5.5% in that time frame, underperforming the S&P 500.\nWill the recent negative trend continue ...</p>\n\n<a href=\"https://finance.yahoo.com/news/bio-rad-bio-down-5-163145298.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PHG","symbol_name":"飞利浦","start_time":0,"source_url":"https://finance.yahoo.com/news/bio-rad-bio-down-5-163145298.html","article_id":"2487986615","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/0K2vxHTAGj_tGrBqjPJ8Cg--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/f889276f4a638f3c7a79c0e3e6b768c1"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2487986615","pubTimestamp":1732897905,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"A month has gone by since the last earnings report for Bio-Rad Laboratories . Shares have lost about 5.5% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Bio-Rad due for a breakout?Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.Bio-Rad posted third-quarter 2024 adjusted earnings per share  of $2.01, which beat the Zacks Consensus Estimate by 57%. However, the bottom line decreased 13.7% from the prior-year quarter’s level.The quarter’s adjustments primarily eliminate the impacts of certain non-recurring items, such as the amortization of purchased intangibles, restructuring costs and losses from the change in the fair market value of equity securities.The company still anticipates non-GAAP currency-neutral revenues to decline 2.5% to 4%. The Zacks Consensus Es","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"PHG":"飞利浦","BIO":"Bio Rad实验室"},"translate_title":"Bio-Rad(BIO)自上次收益报告以来下跌5.5%：能否反弹？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIO":1,"PHG":0.9},"content_text":"A month has gone by since the last earnings report for Bio-Rad Laboratories (BIO). Shares have lost about 5.5% in that time frame, underperforming the S&P 500.\nWill the recent negative trend continue leading up to its next earnings release, or is Bio-Rad due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts. \nBIO Q3 Earnings and Revenues Surpass Estimates\nBio-Rad posted third-quarter 2024 adjusted earnings per share (EPS) of $2.01, which beat the Zacks Consensus Estimate by 57%. However, the bottom line decreased 13.7% from the prior-year quarter’s level.\nThe quarter’s adjustments primarily eliminate the impacts of certain non-recurring items, such as the amortization of purchased intangibles, restructuring costs and losses from the change in the fair market value of equity securities.\nThe company’s GAAP EPS was $23.34, up 541.2% from the year-ago figure of $3.64.\nRevenues in Detail\nRevenues of $649.7 million surpassed the Zacks Consensus Estimate by 2%. The figure also increased 2.8% year over year (up 3.4% at constant exchange rate or CER).\nSegmental Analysis\nSales in the Life Science segment totaled $260.9 million, down 1% year over year and 0.6% at CER. The currency-neutral year-over-year sales decline was broad-based. It was primarily due to weakness in the biotech and biopharma end markets.\nNet sales in the Clinical Diagnostics segment totaled $388.8 million, up 5.6% on a year-over-year basis and 6.4% at CER. Increased demand for quality control products and a favorable comparison for immunology products, which were adversely impacted by supply constraints in the third quarter of 2023, primarily drove the currency-neutral year-over-year sales increase.\nMargins\nIn the quarter under review, Bio-Rad’s gross profit rose 6% to $355.9 million. The gross margin expanded 167 basis points (bps) to 54.8%. \nOperating expenses amounted to $291.4 million, up 19.1% year over year. Operating profit totaled $64.5 million, down 29.1% from the prior-year level. The operating margin contracted 447 bps to 9.9%.\nBIO's Financial Update\nBio-Rad exited the third quarter of 2024 with cash and cash equivalents (including short-term investments) of $1.63 billion compared with $1.62 billion at the end of the second quarter of 2024. Total debt (including current maturities) at the end of the third quarter was $1.20 billion, which remained flat sequentially.\nCumulative net cash flow from operating activities totaled $331 million compared with the year-ago figure of $293.9 million.\n2024 Guidance\nBio-Rad maintained its revenue guidance for full-year 2024.\nThe company still anticipates non-GAAP currency-neutral revenues to decline 2.5% to 4%. The Zacks Consensus Estimate for revenues is pegged at $2.58 billion, implying a 3.4% decline from the 2023 reported figure.\nThe adjusted operating margin for the full year is now projected to be in the range of 12.7-13.2% (up from the earlier guidance of 12-13%).\nHow Have Estimates Been Moving Since Then?\nIt turns out, estimates revision have trended upward during the past month.\nVGM Scores\nCurrently, Bio-Rad has an average Growth Score of C, a grade with the same score on the momentum front. Following the exact same course, the stock was allocated a grade of C on the value side, putting it in the middle 20% for this investment strategy.\nOverall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.\nOutlook\nEstimates have been trending upward for the stock, and the magnitude of this revision looks promising. Notably, Bio-Rad has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.\nPerformance of an Industry Player\nBio-Rad belongs to the Zacks Medical - Products industry. Another stock from the same industry, Royal Philips (PHG), has gained 3.6% over the past month. More than a month has passed since the company reported results for the quarter ended September 2024.\nPhilips reported revenues of $4.81 billion in the last reported quarter, representing a year-over-year change of -1.1%. EPS of $0.35 for the same period compares with $0.36 a year ago.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nBio-Rad Laboratories, Inc. (BIO) : Free Stock Analysis Report\nKoninklijke Philips N.V. (PHG) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2487986615"}